Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies

Editorial

D S Pisetsky. Arthritis Rheum. 2000 Nov.

. 2000 Nov;43(11):2381-2.

doi: 10.1002/1529-0131(200011)43:11<2381::AID-ANR1>3.0.CO;2-M.

No abstract available

Comment in

Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky.
Aringer M, Steiner G, Graninger W, Smolen J. Aringer M, et al. Arthritis Rheum. 2001 Jul;44(7):1721-2. doi: 10.1002/1529-0131(200107)44:7<1721::AID-ART302>3.0.CO;2-J. Arthritis Rheum. 2001. PMID: 11465728 No abstract available.
Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al.
Fautrel B, Foltz V, Frances C, Bourgeois P, Rozenberg S. Fautrel B, et al. Arthritis Rheum. 2002 May;46(5):1408-9; author reply 1409. doi: 10.1002/art.10271. Arthritis Rheum. 2002. PMID: 12115253 No abstract available.
Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis.
Carlson E, Rothfield N. Carlson E, et al. Arthritis Rheum. 2003 Apr;48(4):1165-6; author reply 1166. doi: 10.1002/art.11033. Arthritis Rheum. 2003. PMID: 12687569 No abstract available.
Breaking the ice: Testing tumor necrosis factor alpha blockade in lupus.
Davis JC Jr. Davis JC Jr. Arthritis Rheum. 2004 Oct;50(10):3061-3. doi: 10.1002/art.20577. Arthritis Rheum. 2004. PMID: 15476232 No abstract available.